The American Association for Cancer Research Annual Meeting continues to be a showcase for the most cutting edge science in cancer, and this year's meeting, held here April 2-6, will include an increased focus on clinical trials that will impact patient care.
Daniel D. Von Hoff, M.D., physician-in-chief and distinguished professor at the Translational Genomics Research Institute (TGen), professor of medicine at the Mayo Clinic, and chief scientific officer at Scottsdale Healthcare and U.S. Oncology Research, will host a press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center.
"Scientists in the drug development arena are rethinking how trials are conducted in the wake of so much new knowledge about biomarkers and genetics," he said. "These results will show how it is playing out in both treatment and prevention of lung cancer, breast cancer and other hard to treat malignancies."
The following research will be presented during this press conference:
•New Inhibitor Prevented Lesions, Reduced Tumor Size in Basal Cell Cancer
•BATTLE Researchers Identify New Biomarkers for EGFR Inhibition
•Combining MEK and PI3K Inhibitors Appears Encouraging in a Safety Study with Early Signs of Anti-tumor Activity
•Target for Lung Cancer Chemoprevention Identified
•DNA of 50 Breast Cancer Patients Decoded
Golgi apparatus plays crucial role in enhancing T-cell function against cancer